Part 2 of the Patents Act and Living Organisms Study Series
Quick Answer
India follows a cautious but innovation-supporting approach to biotechnology patents. Patents may protect microorganisms, engineered products and biotechnological processes, but the Patents Act excludes natural discoveries, plants, animals, seeds and essentially biological processes. The framework combines TRIPS compliance with safeguards for public health, biodiversity, farmers and traditional knowledge.
Biotechnology is research-intensive and capital-heavy, but it also concerns living organisms, agriculture, biodiversity and human health. Indian law therefore balances private patent rights with public interest, ethics and environmental protection.
Patents Act and Living Organisms Complete Study Series
- Biotechnology and Patentability in India
- Status of Biotechnology Patents in India
- Evergreening, Sui Generis Protection and Pharmaceutical Patents
How did biotechnology patent law develop in India?
Position under the Patents Act 1970
The original Patents Act adopted a restrictive approach in sensitive areas. In food, medicines and certain chemical substances, it allowed process protection rather than product patents. Biotechnology was not then the major industrial field that it is today, and the treatment of living material was not fully developed.
This approach reflected the objective of encouraging domestic production and limiting monopolies in essential sectors.
Impact of TRIPS
India's membership of the World Trade Organization required compliance with the TRIPS Agreement. TRIPS generally requires patents to be available without discrimination as to the field of technology, but it also preserves specific exclusions, including the flexibility in Article 27.3(b) concerning plants, animals and plant-variety protection.
India amended its patent law in 1999, 2002 and 2005. The 2002 changes modernised several parts of the patent system. The 2005 Amendment completed the transition to product-patent protection for pharmaceuticals and chemicals while retaining and refining safeguards in Section 3.
Exam Note: Product patents for pharmaceuticals were introduced through the 2005 Amendment, not the 2002 Amendment.
What biotechnology inventions can receive patents?
The current framework may protect an invention that satisfies novelty, inventive step and industrial applicability and is not excluded by the Act.
| Category | General position |
|---|---|
| Engineered microorganisms | May be patentable when they are not mere discoveries from nature |
| Biotechnology processes | Recombinant, fermentation and microbial processes may qualify |
| Vaccines, enzymes and biological products | May qualify when claimed as patentable products or processes |
| Engineered biological material | Requires a genuine technical contribution, disclosed function and industrial application |
| Industrial and environmental biotechnology | Waste-treatment, bioenergy and microbial applications may qualify |
Where a microorganism cannot be adequately described in writing, the disclosure rules may require deposit with an international depositary authority. The Budapest Treaty supports recognition of such deposits for patent procedure.
Which biotechnology inventions are excluded?
The main limits arise from Section 3 of the Patents Act.
- Section 3(b) addresses inventions whose use would be contrary to public order or morality or seriously harmful to life, health or the environment.
- Section 3(c) excludes mere discoveries of scientific principles, living things and substances occurring in nature.
- Section 3(d) restricts patents on new forms of known substances unless the statutory efficacy requirement is satisfied.
- Section 3(i) excludes methods for medical and specified diagnostic treatment of humans or animals.
- Section 3(j) excludes plants and animals, including seeds, varieties, species and essentially biological processes, while excepting microorganisms.
These provisions make Indian law stricter in areas involving agriculture, natural biological material and pharmaceutical modifications.
Which cases shaped biotechnology patent law?
Dimminaco AG v Controller of Patents
The Calcutta High Court considered a process for preparing a vaccine whose final product contained living organisms. It held that the presence of living material did not by itself prevent the process from being treated as an invention. This decision helped establish that biotechnology processes are not automatically excluded.
Novartis AG v Union of India
The Supreme Court applied Section 3(d) to the beta crystalline form of imatinib mesylate. It held that the material placed before the Court did not establish the required enhancement of therapeutic efficacy. The official Supreme Court judgment remains central to pharmaceutical and biotechnology patent study.
Monsanto Technology LLC v Nuziveedu Seeds Ltd
The dispute concerned patent claims relating to Bt cotton technology and the interaction between patent law and plant-variety protection. The Delhi High Court Division Bench had ruled on Section 3(j), but the Supreme Court later set aside that judgment and restored the Single Judge's interim order, leaving the substantive issues for trial. The official Supreme Court judgment dated 8 January 2019 should therefore be read before treating the earlier Delhi High Court reasoning as a final determination.
Key distinction: The Supreme Court did not finally declare every gene or trait claim relating to a plant unpatentable in the Monsanto appeal.
How does India differ from other jurisdictions?
The United States historically adopted a broader approach after Diamond v Chakrabarty, which concerned a genetically engineered bacterium. Its Supreme Court later limited gene patenting in Myriad Genetics by excluding naturally occurring DNA merely isolated from the body.
Europe also permits biotechnology patents within statutory and morality-based limits. India uses the flexibility preserved by TRIPS more cautiously, particularly for plants, seeds and natural biological material.
How are farmers rights and biodiversity protected?
Plant varieties are protected separately under the Protection of Plant Varieties and Farmers' Rights Act, 2001. This system recognises breeders while preserving defined farmers' rights.
The Biological Diversity Act, 2002, as amended in 2023 with the amendments brought into force from 1 April 2024, regulates access to biological resources, intellectual-property applications and benefit-sharing under its current framework.
India also uses the Traditional Knowledge Digital Library to help prevent patents based on already known traditional medicinal knowledge. The turmeric and neem disputes illustrate why documented prior knowledge matters to patent examination.
What is the present status of biotechnology patents?
The position may be described as cautiously progressive. India protects genuine human-made biotechnology inventions, including eligible microorganisms, vaccines, industrial processes and engineered products. At the same time, it uses Section 3 and specialised legislation to protect public health, agricultural interests, traditional knowledge and biodiversity.
This can make protection narrower than in some jurisdictions, particularly for plant-related inventions. Supporters regard the restrictions as necessary public-interest safeguards, while critics argue that uncertainty may affect investment. The legal result depends on the precise claim, technical contribution and statutory exclusion involved.
Key Takeaways
- India's biotechnology-patent regime developed through the 1999, 2002 and 2005 amendments.
- Product patents in pharmaceuticals returned in 2005.
- Human-made microorganisms and biotechnology processes may qualify for patents.
- Natural discoveries, plants, animals and treatment methods remain excluded.
- Patent law works with farmers' rights, biodiversity and traditional-knowledge protection.
- The Monsanto dispute should not be reduced to a final blanket ruling against all gene-related claims.
Frequently Asked Questions
Is biotechnology patentable in India?
Yes, but only where the claimed invention satisfies the ordinary patentability requirements and does not fall within a statutory exclusion.
Are microorganisms patentable?
Non-naturally occurring or engineered microorganisms may be patentable. A microorganism merely discovered in nature is subject to Section 3(c).
Are plants and seeds patentable?
No. Section 3(j) excludes plants, seeds, varieties and species. Plant varieties are dealt with through the PPVFR Act.
Did Monsanto finally decide that all gene sequences are unpatentable?
No. The Supreme Court set aside the Division Bench judgment and restored the earlier interim order so that the substantive issues could be considered at trial.
Does biotechnology patent law operate independently of biodiversity law?
No. Where Indian biological resources or associated knowledge are involved, the amended Biological Diversity Act may also apply.
Continue Reading
Previous: Biotechnology and Patentability in India
Next: Evergreening, Sui Generis Protection and Pharmaceutical Patents